Targeting Vasopressin 2 Receptor (V2R) in Renal Cystogenesis by Exploring the Nephroprotective Potential of “Terminalia arjuna”

Year : 2024 | Volume : 13 | Issue : 02 | Page : 14 24
    By

    Bhargavi. G,

  1. Student, Department of Biotechnology, MES College of Arts, Commerce and Science Malleshwaram, Bengaluru, Karnataka, India

Abstract

Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, leading to the formation of multiple cysts in the kidneys. It is a major cause of end-stage renal disease (ESRD), which often requires dialysis or a kidney transplant for survival. This research focuses on identifying potential bioactive compounds derived from natural sources that show promise for drug development targeting the V2R gene. Methods: The naturally occurred phytochemical compounds in Terminalia arjuna have multiple bioactive properties in the medical field. Drug illness prediction, molecular docking, and absorption, distribution, metabolism, and excretion (ADME) analysis were employed to identify the most suitable ligand candidates for drug development. The V2R protein and its chains were retrieved from the Protein Data Bank (PDB) after undergoing purification. Ligands with poor binding affinity to the target protein were excluded from further analysis. To evaluate drug-likeness, ADMET and Swiss-ADME analyses were performed. Molecular docking simulations were conducted using PyRx. Additionally, the Ramachandran plot was utilized to illustrate the torsion angles Φ and ψ within the protein backbone, offering insights into the structural conformation. Results: The phytocompound found in Terminalia arjuna has a potential binding affinity with V2R found in molecular docking. ADMET profile and docking showed only one compound with the highest binding affinity, that is arjunolic acid, was found to be the best, which can pose the properties of drugs. Conclusion: The bioactive compounds identified in this study could be regarded as potential drug candidates for inhibiting renal cytogenesis, owing to their promising binding affinity with both structural and non-structural proteins of the virus. These findings suggest that these compounds may play a crucial role in therapeutic strategies aimed at targeting renal disease progression

Keywords: Hereditary kidney disease, bioactive compounds, renal cytogenesis inhibition, potential binding affinity, ADMET

[This article belongs to Research & Reviews : Journal of Computational Biology ]

How to cite this article:
Bhargavi. G. Targeting Vasopressin 2 Receptor (V2R) in Renal Cystogenesis by Exploring the Nephroprotective Potential of “Terminalia arjuna”. Research & Reviews : Journal of Computational Biology. 2024; 13(02):14-24.
How to cite this URL:
Bhargavi. G. Targeting Vasopressin 2 Receptor (V2R) in Renal Cystogenesis by Exploring the Nephroprotective Potential of “Terminalia arjuna”. Research & Reviews : Journal of Computational Biology. 2024; 13(02):14-24. Available from: https://journals.stmjournals.com/rrjocb/article=2024/view=180802


Browse Figures

References

  1. Altarac S. Simple renal cysts. Lijecnicki Vjesnik. 2004;126(9-10):260–26
  2. Lu Y, Hu J, Feng N. Evolution of renal cyst to renal carcinoma: a case report and review of literature. J Clin Exp Pathol. 2021;14(4):463–46
  3. Lanktree MB, Haghighi A, di Bari I, Song X, Pei Y. Insights into autosomal dominant polycystic kidney disease from genetic studies. Clin J Am Soc Nephrol. 2021;16(5):790–79 doi:10.2215/CJN.02320220.
  4. Cornec‐Le GE, Audrézet MP, Le MY, Chen JM, Férec C. Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on. Human Mutat. 2014;35(12):1393–1 doi:10.1002/humu.227.
  5. Douguet D, Patel A, Honoré E. Structure and function of polycystins: insights into polycystic kidney disease. Nat Rev Nephrol. 2019;15(7):412–4 doi:10.1038/s41581-019-0143-6.
  6. Ram G, Kumar A, Hemlata, Singh G, Giri SK. In silico screening and molecular docking study of compounds from Pedalium murex L. with Vasopressin2 receptor target for autosomal dominant polycystic kidney d Beni-Suef Univ J Basic Appl Sci. 2021;10:1–8. doi:10.1186/s43088-021-00149-0.
  7. Di Mise A, Wang X, Ye H, Pellegrini L, Torres VE, Valenti G. Pre‐clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB J. 2021;35(10):e21874. doi:10.1096/fj.202100774R.
  8. Gonzalez AA, Salinas-Parra N, Cifuentes-Araneda F, Reyes-Martinez C. Vasopressin actions in the kidney renin angiotensin system and its role in hypertension and renal disease. Vitamin Horm. 2020;113:217–2 doi:10.1016/bs.vh.2019.09.003.
  9. Hogan MC, Masyuk TV. Concurrent targeting of vasopressin receptor 2 and somatostatin receptors in autosomal dominant polycystic kidney disease: A promising approach for autosomal dominant polycystic kidney disease treatment? Clin J Am Soc Nephrol. 2023;18(2):154–15 doi:10.2215/
    CJN.0000000000000055.
  10. Kumar V, Sharma N, Saini R, Mall S, Zengin G, Sourirajan A, Khosla PK, Dev K, El-Shazly M. Therapeutic potential and industrial applications of Terminalia arjuna bark. J Ethnopharmacol. 2023;310:116352. doi:10.1016/j.jep.2023.116352.
  11. Kuleshwar JT, Thakur N. Pharmacological approach of Terminalia arjuna: A review. Plant Cell Biotechnol Mol Biol. 2021;22(57 & 58):1–15.
  12. Gallagher AR, Germino GG, Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv Chron Kidney D 2010;17(2):118–130. doi:10.1053/j.ackd.2010.01.002.
  13. Sparapani S, Millet-Boureima C, Oliver J, Mu K, Hadavi P, Kalostian T, Ali N, Avelar CM, Bardies M, Barrow B, Benedikt M. The biology of vasopressin. Biomed. 2021;9(1):89. doi:10.3390/bio
  14. Dwivedi S, Kushalan S, Paithankar JG, D’Souza LC, Hegde S, Sharma A. Environmental toxicants, oxidative stress and health adversities: interventions of phytochemicals. J Pharm Pharmacol. 2022;74(4):516–5 doi:10.1093/jpp/rgab044.
  15. Devi A, Dev P. Emerging therapeutic properties of Terminalia Arjuna: A review. Int J Novel Res Devel. 2024;9(2):449–454.
  16. Lai X, Bacallao RL, Blazer-Yost BL, Hong D, Mason SB, Witzmann FA. Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients. Proteomics Clin Appl. 2008;2(7–8):1140–11 doi:10.1002/prca.200780140.
Regular Issue Subscription Original Research
Volume 13
Issue 02
Received 02/09/2024
Accepted 07/10/2024
Published 04/11/2024
151

Login


My IP

PlumX Metrics